So now the question is: Why is Flaskworks developing a different but similar automated system for NWBO, that might work with other cell products, such as CAR T? Thanks for your research, XMaster. I keep thinking of the (annual?) report that said the Flaskworks team was working on Direct, possibly to get it ready for new clinical trials. Idon't know if Direct needs an EDEN-like automated device.
Market Data 
Markets 
AI
